Formulation and Evaluation of Bilayer of Omeprazole Sustained release action

The purpose of present study is to formulate the bilayer tablets containing omeprazole and diclofenac sodium.In this single tablet omeprazole is in immediate release portion and diclofenac sodium is in sustained released portion.This combination of medicine can be used in the person who are at the threat of developing stomach ulcers.Omeprazole act to relieve ulcers and diclofenac manage to relieve pain due to ulcer.Hence, the layered tablets offer a pharmacokinetic advantage over conventional controlled release lozenge forms as the medicine is snappily released from the fast release subcaste leading to rapid-fire rise of medicine tube attention followed by durability of medicine release from the sustained release subcaste.The optimized immediate release subcaste is named from batches OIR9 grounded on medicine release, wetting down time, and decomposition time.The sustained release tablets are optimized using factorial design for dragged medicine release of diclofenac sodium.Floating bioadhesive tablets are prepared using guar goo and xanthan goo as DSR9 expression.The final bilayer tablet expression (BODT1 -BODT9) is prepared using optimized batches from different polymer combinations.The bilayer tablets parade a unique combination of floatation and bioadhesion for prolonged hearthstone in the stomach and quick onset of action.The polymer-to-medicine rate significantly affects floating pause time and medicine release kinetics.Guar goo and xanthan goo also impact swelling indicator, gastric mucosa adhesion, gastric retention, and in-vitro medicine release rate profile.The optimized expression BODT9 is best suited for GRDDS.